Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCH: Weekly vs Every-3-Week Trastuzumab, Paclitaxel, and Carboplatin in HER2+ Breast Cancer
NCT01170143Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Aug 2009
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: pathological complete response rate at 3 years. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01170143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170143.